用于精神分裂症患者的HMG辅酶A还原酶抑制剂（他汀类药物）与安慰剂的对比研究
HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia.
作者信息
Saishoji Yusuke, Kim Saehyeon, Banno Masahiro, Kohmura Kunihiro, Kataoka Yuki, Tsujimoto Yasushi
机构信息
Department of General Medicine, Hakujyuji Hospital, Fukuoka, Japan.
Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.
出版信息
Cochrane Database Syst Rev. 2025 Sep 19;9(9):CD014565. doi: 10.1002/14651858.CD014565.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of HMG-CoA reductase inhibitors (statins) compared with placebo for schizophrenia in adults.
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：评估与安慰剂相比，成人精神分裂症患者使用HMG辅酶A还原酶抑制剂（他汀类药物）的益处和危害。
相似文献
1
HMG-CoA reductase inhibitors (statins) versus placebo for people with schizophrenia.用于精神分裂症患者的HMG辅酶A还原酶抑制剂（他汀类药物）与安慰剂的对比研究
Cochrane Database Syst Rev. 2025 Sep 19;9(9):CD014565. doi: 10.1002/14651858.CD014565.
2
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.用于非透析慢性肾病患者的HMG辅酶A还原酶抑制剂（他汀类药物）
Cochrane Database Syst Rev. 2014 May 31(5):CD007784. doi: 10.1002/14651858.CD007784.pub2.
3
HMG CoA reductase inhibitors (statins) for dialysis patients.用于透析患者的HMG CoA还原酶抑制剂（他汀类药物）。
Cochrane Database Syst Rev. 2013 Sep 11;2013(9):CD004289. doi: 10.1002/14651858.CD004289.pub5.
4
HMG CoA reductase inhibitors (statins) for kidney transplant recipients.肾移植受者使用的HMG CoA还原酶抑制剂（他汀类药物）
Cochrane Database Syst Rev. 2014 Jan 28;2014(1):CD005019. doi: 10.1002/14651858.CD005019.pub4.
5
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.用于非透析慢性肾脏病患者的HMG辅酶A还原酶抑制剂（他汀类药物）
Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
6
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.用于预防心脏搭桥手术后急性肾损伤的HMG CoA还原酶抑制剂（他汀类药物）。
Cochrane Database Syst Rev. 2015 Mar 11;2015(3):CD010480. doi: 10.1002/14651858.CD010480.pub2.
7
Preoperative statin therapy for adults undergoing cardiac surgery.心脏手术成人患者的术前他汀治疗。
Cochrane Database Syst Rev. 2024 Jul 22;7(7):CD008493. doi: 10.1002/14651858.CD008493.pub5.
8
HMG CoA reductase inhibitors (statins) for dialysis patients.用于透析患者的HMG CoA还原酶抑制剂（他汀类药物）。
Cochrane Database Syst Rev. 2009 Jul 8(3):CD004289. doi: 10.1002/14651858.CD004289.pub4.
9
HMG CoA reductase inhibitors (statins) for dialysis patients.用于透析患者的HMG CoA还原酶抑制剂（他汀类药物）。
Cochrane Database Syst Rev. 2009 Apr 15(2):CD004289. doi: 10.1002/14651858.CD004289.pub3.
10
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.用于非透析慢性肾病患者的HMG辅酶A还原酶抑制剂（他汀类药物）
Cochrane Database Syst Rev. 2009 Apr 15(2):CD007784. doi: 10.1002/14651858.CD007784.
本文引用的文献
1
Standardized mean differences in meta-analysis: A tutorial.荟萃分析中的标准化均数差：教程
Cochrane Evid Synth Methods. 2024 Mar 10;2(3):e12047. doi: 10.1002/cesm.12047. eCollection 2024 Mar.
2
Lack of Efficacy of Simvastatin Adjunctive Therapy for Patients with Schizophrenia: A Meta-Analysis of Randomized Controlled Trials.辛伐他汀辅助治疗精神分裂症患者的疗效缺乏：一项随机对照试验的荟萃分析。
Neuropsychiatr Dis Treat. 2024 Sep 6;20:1667-1675. doi: 10.2147/NDT.S480921. eCollection 2024.
3
Statins as an adjuvant therapy for patients with schizophrenia: An up-to-date systematic review and meta-analysis.他汀类药物作为精神分裂症患者的辅助治疗：最新的系统评价和荟萃分析。
Gen Hosp Psychiatry. 2024 Jul-Aug;89:75-83. doi: 10.1016/j.genhosppsych.2024.05.001. Epub 2024 May 7.
4
A core outcome set for trials evaluating self-management interventions in people with severe mental illness and coexisting type 2 diabetes.用于评估重度精神疾病合并2型糖尿病患者自我管理干预措施的试验的核心结局集。
Diabet Med. 2024 Apr;41(4):e15288. doi: 10.1111/dme.15288. Epub 2024 Jan 18.
5
Poverty and inequality in real-world schizophrenia: a national study.现实世界中精神分裂症的贫困和不平等：一项全国性研究。
Front Public Health. 2023 Oct 31;11:1182441. doi: 10.3389/fpubh.2023.1182441. eCollection 2023.
6
Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes.精神分裂症的临床结局评估工具：一项以患者报告结局的潜力为重点的范围性文献综述
Innov Clin Neurosci. 2023 Spring;20(4-6):14-33.
7
Review of Major Social Determinants of Health in Schizophrenia-Spectrum Psychotic Disorders: I. Clinical Outcomes.精神分裂症谱系及精神病性障碍的主要社会决定因素综述：I. 临床转归。
Schizophr Bull. 2023 Jul 4;49(4):837-850. doi: 10.1093/schbul/sbad023.
8
A systematic review of social functioning outcome measures in schizophrenia with a focus on suitability for intervention research.一项针对精神分裂症社会功能结局测量的系统评价，重点关注干预研究的适用性。
Schizophr Res. 2022 Mar;241:275-291. doi: 10.1016/j.schres.2022.02.011. Epub 2022 Feb 22.
9
Instruments to assess quality of life in people with mental health problems: a systematic review and dimension analysis of generic, domain- and disease-specific instruments.评估心理健康问题人群生活质量的工具：通用、领域和疾病特异性工具的系统评价和维度分析。
Health Qual Life Outcomes. 2021 Nov 2;19(1):249. doi: 10.1186/s12955-021-01883-w.
10
Developing an International Standard Set of Patient-Reported Outcome Measures for Psychotic Disorders.制定一套针对精神障碍的国际患者报告结局测量标准集。
Psychiatr Serv. 2022 Mar 1;73(3):249-258. doi: 10.1176/appi.ps.202000888. Epub 2021 Aug 9.
Zotero 插件